SC
SGMT icon

Steven Cohen’s Sagimet Biosciences SGMT Stock Holding History

Steven Cohen’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,100
Closed -$108K – 2490
2024
Q4 		$108K Sell
24,100
-50,100
-68% -$254K ﹤0.01% 1957
2024
Q3 		$206K Buy
+74,200
New +$229K ﹤0.01% 1783

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Steven Cohen's SGMT Position: Q2 2026 in Review

Steven Cohen sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 187,564 shares — an estimated $980K sold.

Steven Cohen first reported a position in SGMT in Q1 2024 and held it in 7 quarters. The position peaked at $14.5M in Q1 2024. 121 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Steven Cohen reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 187,564 Sagimet Biosciences shares in Q2 2026, an estimated $980K.
  • Steven Cohen first reported a position in Sagimet Biosciences in Q1 2024 and held it in 7 quarters.
  • Steven Cohen's Sagimet Biosciences position peaked at $14.5M in Q1 2024.
  • 121 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.